Adverum Biotechnologies Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Laurent Fischer
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 43.4% |
| CEO tenure | 4yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.4yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Adverum ticks lower on underwhelming data from gene therapy in wet-AMD
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$113m |
| Dec 31 2023 | US$2m | US$672k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$126m |
| Jun 30 2023 | n/a | n/a | -US$133m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$3m | US$646k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$155m |
| Dec 31 2021 | US$9m | US$621k | -US$146m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$138m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | US$22m | US$327k | -US$118m |
Compensation vs Market: Laurent's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD1.55M).
Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.
CEO
Laurent Fischer (60 yo)
4yrs
Tenure
US$1,546,477
Compensation
Dr. Laurent Fischer, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He served as a Senior Advisor of Frazier Management,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | US$1.55m | 0.34% $ 536.6k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.5yrs | US$2.30m | 0.048% $ 76.2k | |
| Chief Operating Officer | 3yrs | US$903.02k | 0.13% $ 211.8k | |
| Chief Development Officer | 2.4yrs | US$799.36k | 0.026% $ 40.9k | |
| Chief Medical Officer | no data | US$94.20k | 0% $ 0 | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior VP & General Counsel | 2.9yrs | US$1.33m | 0.031% $ 49.4k | |
| Chief People Officer | 4.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.4yrs | no data | no data | |
| Senior Vice President of Quality | 2.7yrs | no data | no data | |
| Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations | no data | no data | no data |
2.4yrs
Average Tenure
56.5yo
Average Age
Experienced Management: ADVM's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | US$1.55m | 0.34% $ 536.6k | |
| Independent Director | 5.1yrs | US$111.70k | 0.050% $ 78.7k | |
| Independent Director | 4.2yrs | US$106.70k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Chairman | 7.3yrs | US$163.80k | 0.042% $ 67.2k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 3.3yrs | US$99.20k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$106.70k | 0.024% $ 38.1k | |
| Independent Director | 5.1yrs | US$99.20k | 0.063% $ 99.1k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Director | no data | no data | no data |
4.1yrs
Average Tenure
63yo
Average Age
Experienced Board: ADVM's board of directors are considered experienced (4.1 years average tenure).